Global pharmacogenetics: Giving the genome to the masses

Pharmacogenomics

Volumn 7, Issue 4, 2006, Pages 625-631

  Marsh, Sharon ^a,b   Van Booven, Derek J ^a   McLeod, Howard L ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

Author keywords

FDA; Genotype; Global healthcare; PGENI; Pharmacogenetics; Pharmacogenomics; Polymorphism; World Health Organization

Indexed keywords

ANESTHETIC AGENT; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; FLUOROURACIL; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE T1; IRINOTECAN; PSYCHOTROPIC AGENT; THYMIDYLATE SYNTHASE; WARFARIN;

ARTICLE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DNA POLYMORPHISM; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG METABOLISM; ETHNOLOGY; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC DISORDER; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN GENOME; HUMAN IMMUNODEFICIENCY VIRUS; PHARMACOGENETICS; RECTUM CANCER; TOXICITY TESTING; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

EID: 33745165575     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.7.4.625     Document Type: Article

References (68)

1. Wysowski DK, Swartz L: Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch, Intern. Med. 165, 1363-1369 (2005).
2. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286, 2270-2279 (2001).
3. Evans WE, McLeod HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538-549 (2003).
4. Marsh S, McLeod HL: Cancer pharmacogenetics. Br. J. Cancer 90, 8-11 (2004).
5. Cresi S: The PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics. Expert Opin. Pharmacother. 6, 2577-2591 (2005).
6. MacPhee IA, Fredericks S, Holt DW: Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation? Expert Opin. Pharmacother. 6, 2593-2605(2005).
7. Quirk E, McLeod H, Powderly W: The pharmacogenetics of antiretroviral therapy: a review of studies to date. Clin. Infect. Dis. 39, 98-106 (2004).
8. Ranganathan P, Eisen S, Yokoyama WM, McLeod HL: Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann. Rheum. Dis. 62, 4-9 (2003).
9. Gupta S, Jain S, Brahmachari SK, Kukreti R: Pharmacogenomics: a path to predictive medicine for schizophrenia. pharmacogenomics 7, 31-47 (2006).
10. Lander ES, Linton LM, Birren B et al.: Initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001).
11. Sachidanandam R, Weissman D, Schmidt SC et al.: A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409, 928-933 (2001).
12. Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P: A haplotype map of the human genome. Nature 437, 1299-1320 (2005).
13. Marcelin AG, Flandre P, Peytavin G, Calvez V: Predictors of virologic response to ritanavir-boosted protease inhibitors. AIDS Rev. 7, 225-232 (2005).
14. Barnes PF, Cave MD: Molecular epidemiology of tuberculosis. N. Engl. J. Mad. 349, 1149-1156 (2003).
15. Drumn ML, Konstan MW, Schluchter MD et al.: Genetic modifiers of lung disease in cystic fibrosis. N. Engl. J. Med. 353, 1443-1453 (2005).
16. Nabel EG: Cardiovascular disease. N Engl. J. Med. 349, 60-72 (2003).
17. Marsh S, McLeod HL: Pharmacogenetics of irinotecan toxicity. Pharmacogenetics 5, 835-843 (2004).
18. FDA clears Third Wave pharmacogenetic test. Pharmacogenomics 6, 671-672 (2005).
19. AmpliChip CYP450 test. Med. Lett. Drugs Ther. 47, 71-72 (2005).
20. Candiotti KA, Birnbach DJ, Lubarsky DA et al.: The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology 102, 543-549 (2005).
21. Marsh S: Thymidylate synthase pharmacogenetics. Invest. New Drugs 23, 533-537 (2005).
22. McLeod HL, Tan B, Malyapa R et al.: Genotype-guided neoadjuvant therapy for rectal cancer. Proc. Am. Soc. Clin. Oncol. 23, 197 (2005).
23. Voora D, Eby C, Linder MW et al.: Prospective dosing of warfarin based on cytochrome P450 2C9 genotype. Thromb. Haemost. 93, 700-705 (2005).
24. Meadows M: FDA issues guidance on race and ethnicity data. FDA Consum. 37, 36 (2003).
25. Schultz J: FDA guidelines on race and ethnicity: obstacle or remedy? J. Natl Cancer Inst. 95, 425-426 (2003).
26. Tate SK, Goldstein DB: Will tomorrow's medicines work for everyone? Nature Genet. 36, S34-S42 (2004).
27. Garte S, Gaspari L, Alexandrie AK et al.: Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol. Biomarkers Prev. 10, 1239-1248 (2001).
28. Engen RM, Marsh S, Van Booven DJ, McLeod HL: Ethnic differences in pharmacogenetically relevant genes. Current Drug Targets (In press) (2006).
29. Watanabe J, Hayashi S, Kawajiri K: Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5′-flanking region. J. Biochem. (Tokyo). 116, 321-326 (1994).
30. Hamdy SI, Hiratsuka M, Narahara K et al.: Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1 and dihydropyrimidine debydrogenase (DPYD) in the Egyptian population. Br J. Clin. Pharmacol. 53, 596-603 (2002).
31. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Vainio H: The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis 14, 85-88 (1993).
32. Mendoza-Cantu A, Castorena-Torres F, Bermudez M et al.: Genotype and allele frequencies of polymorphic cytochromes P450 CYP1A2 and CYP2E1 in Mexicans. Cell Biochem. Fund. 22, 29-34 (2004).
33. Colombo J. Rossit AR, Caetano A, Borim AA, Wornrath D, Silva AE: GSTT1, GSTM1 and CYP2E1 genetic polymorphisms in gastric cancer and chronic gastritis in a Brazilian population. World J. Gastroenterol. 10, 1240-1245 (2004).
34. Quinones L, Lucas D, Goday J et al.: CYP1A1, CYP2E1 and GSTM1 genetic polymorphisms. The effect of single and combined genotypes on lung cancer susceptibility in Chilean people. Cancer Lett. 174, 35-44 (2001).
35. Chao YC, Young TH, Chang WK, Tang HS, Hsu CT An investigation of whether polymorphisms of cytochrome P4502E1 are genetic markers of susceptibility to alcoholic end-stage organ damage in a Chinese population. Hepatology 22, 1409-1414 (1995).
36. Sarmanova J, Tynkova L, Susova S, Gut I, Soucek P: Genetic polymorphisms of biotransformation enzymes: allele frequencies in the population of the Czech Republic. Pharmacogenetics 10, 781-788 (2000).
37. Savolainen VT, Pajarinen J, Perola M, Penttila A, Karhunen PJ: Polymorphism in the cytochrome P450 2E1 gone and the risk of alcoholic liver disease. J. Hepatol. 26, 55-61 (1997).
38. Lucas D, Menez C, Floch F et al.: Cytochromes P4502E1 and P4501A1 genotypes and susceptibility to cirrhosis or upper aerodigestive tract cancer in alcoholic caucasians. Alcohol Clin. Exp. Res. 20, 1033-1037 (1996).
39. Pastorelli R, Bardazzi G, Saieva C et al.: Genetic determinants of alcohol addiction and metabolism: a survey in Italy. Alcohol Clin. Exp. Res. 25, 221-227 (2001).
40. Watanabe J, Hayashi S, Nakachi K et al.: PstI and RsaI RFLPs in complete linkage disequilibrium at the CYP2E gene. Nucleic Acids Res. 18, 7194 (1990).
41. Lee HC, Lee HS, Jung SH et al.: Association between polymorphisms of ethanol-metabolizing enzymes and susceptibility to alcoholic cirrhosis in a Korean male population. J. Korean Med. Sci. 16, 745-750 (2001).
42. Ladero JM, Agundez JA, Rodriguez-Lescure A, Diaz-Rubio M, Benitez J: RsaI polymorphism at the cytochrome, P4502E1 locus and risk of hepatocellular carcinoma. Gut 39, 330-333 (1996).
43. Persson I, Johansson I, Bergling H et al.: Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett. 319, 207-211 (1993).
44. Kongruttanachok N, Sukdikul S, Setavarin S et al.: Cytochrome P4502E1 polymorphism and nasopharyngeal carcinoma development in Thailand: a correlative study. BMC Cancer 1, 4 (2001).
45. Omer B, Ozbek U, Akkose A, Kilic GL Genetic polymorphism of cytochrome P450 2E1 in the Turkish population. Cell Biochem. Funct. 19, 273-275 (2001).
46. Stephens EA, Taylor JA, Kaplan N et al.: Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics 4, 185-192 (1994).
47. Korytina GF, Yanbaeva DG, Babenkova LI, Etkina EI, Victorova TV: Genetic polymorphisms in the cytochrome P450 (1A1, 2E1), microsomal epoxide hydrolase and glutathione S-transferase M1, T1, and P1 genes, and their relationship with chronic bronchitis and relapsing pneumonia in children. J. Mol. Med. 83, 700-710 (2005).
48. Butler WJ, Ryan P, Roberts-Thomson IC: Metabolic genotypes and risk for colorectal cancer. J. Gastroenterol. Hepatol. 16, 631-635 (2001).
49. Ferreira PM, Medeiros R, Vasconcelos A et al.: Association between CYP2E1 polymorphisms and susceptibility to prostate cancer. Eur. J Cancer Prev. 12, 205-211 (2003).
50. Yang B, O'Reilly DA, Demaine AG, Kingsnorth AN: Study of polymorphisms in the CYP2E1 gone in patients with alcoholic pancreatitis. Alcohol 23, 91-97 (2001).
51. Zavras AI, Wu T, Laskaris G et al.: Interaction between a single nucleotide polymorphism in the alcohol dehydrogenase 3 gene, alcohol consumption and oral cancer risk. Int J Cancer 97, 526-530 (2002).
52. Gajecka M, Rydzanicz M, Jaskula-Sztul R, Kujawski M, Szyfter W, Szyfter K: CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. Mutat Res. 574, 112-123 (2005).
53. Sobti RC, Sharma S, Joshi A, Jindal SK, Janmeja A: Genetic polymorphism of the CYP1A1, CYP2E1, GSTM1 and GSTT1 genes and lung cancer susceptibility in a North Indian population. Mol. Cell Biochem. 266, 1-9 (2004).
54. Sepehr A, Kamangar F, Abnet CC et al.: Genetic polymorphisms in three Iranian populations with different risks of esophageal cancer, an ecologic comparison. Cancer Lett. 213, 195-202 (2004).
55. Infante-Rivard C, Krajinovic M, Labuda D, Sinnett D: Childhood acute lymphoblastic leukemia associated with parental alcohol consumption and polymorphisms of carcinogen-metabolizing genes. Epidemiology 13, 277-281 (2002).
56. Li D, Dandara C, Parker MI: Association of cytochrome P4502E1 genetic polymorphisms with squamous cell carcinoma of the oesophagus. Clin. Chem. Lab. Med. 43, 370-375 (2005).
57. Naccarati A, Soucek P, Stetina R et al.: Genetic polymorphisms and possible gene-gene interactions in metabolic and DNA repair genes: effects on DNA damage. Mutat. Res. 593(1-2), 22-31 (2006).
58. Sarmanova J, Benesova K, Gut I, Nedelcheva-Kristensen V, Tynkova L, Soucek P: Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas. Hum. Mol. Genet 10, 1265-1273 (2001).
59. Kiss I, Sandor J, Pajkos G, Bogner B, Hegedus G, Ember I: Colorectal cancer risk in relation to genetic polymorphism of cytochrome P4501A1, 2E1, and glutathione-S-transflerase M1 enzymes. Anticancer Res. 20, 519-522 (2000).
60. Martinez C, Agundez JA, Olivera M et al.: Influence of genetic admixture on polymorphisms of drug-metabolizing enzymes: analyses of mutations on NAT2 and C γ P2E1 gem in a mixed Hispanic population. Clin Pharmacol. Ther. 63, 623-628 (1998).
61. Bakayev VV, Mohammadi F, Bahadori M et al.: Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals. Eur J. Clin. Pharmacol 60, 467-471 (2004).
62. Bell DA, Taylor JA, Butler MA et al.: Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a now slow-acetylator allele common in African-Americans. Carcinogenesis 14, 1689-1692 (1993).
63. Ilett KF, Chiswell GM, Spargo RM, Platt E, Minchin RF: Acetylation phenotype and genotype in aboriginal leprosy patients from the north-west region of Western Australia. Pharmacogenetics 3, 264-269 (1993).
64. Kukongviriyapan V, Prawan A, Tasseneyakul W, Aiemsa-Ard J, Warasiha B: Arylamine N-acetyltransf-2 genotypes in the Thai population. Br. J. Clin. Pharmacol. 55, 278-281 (2003).
65. Meyer UA, Zanger UM: Molecular mechanisms of genetic polymorphisms of Drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37, 269-296 (1997).
66. Risch A, Wallace DM, Bathers S, Sim E: Slow N-acetylation genotype is a susceptibility factor in occupational and smoking-related bladder cancer. Hum. Mol. Genet. 4, 231-236 (1995).
67. Hogerzeil HV: The concept of essential medicines: lessons for rich countries. BMJ 329, 1169-1172 (2004).
68. Laing R, Waning B, Gray A, Ford N, 't Hoen E: 25 years of the WHO essential medicines lists: progress and challenges. Lancet 361, 1723-1729 (2003).